⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NBIX News
Neurocrine Biosciences Inc
Pharmazz, Inc. Appoints Ajay Bansal as Chief Financial Officer
globenewswire.com
LEGN
NBIX
4basebio Announces Appointment of Chief Financial Officer and Board Changes
globenewswire.com
NBIX
MREO
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
prnewswire.com
NBIX
Nona Biosciences Evolves Brand to Reflect Next Phase of Growth in Biotherapeutic Innovation
prnewswire.com
NBIX
Form 8-K
sec.gov
NBIX
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
prnewswire.com
NBIX
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026
prnewswire.com
NBIX
Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment
prnewswire.com
NBIX
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist
prnewswire.com
NBIX
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
prnewswire.com
NBIX